Delving into the Latest Updates on BCM-235 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

BCM 235, BCM-235, BCM235

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesNervous System DiseasesMouth and Tooth Diseases+ [3]

Active Indication

ArthralgiaCommon ColdFever+ [8]

Inactive Indication-

Originator Organization

Shanghai Bocimed Pharmaceutical Co., Ltd.

Active Organization

Shanghai Bocimed Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

预试验：对BCM235缓释干混悬剂和布洛芬混悬液的PK参数进行初步的探索性评价，为下一步临床研究提供依据。单/多次给药PK研究：主要目的：以上海强生制药有限公司生产的布洛芬混悬液做对照，研究BCM235缓释干混悬剂的药代动力学特征和生物利用度，同时考察BCM235缓释干混悬剂和布洛芬混悬液间的生物等效性。次要目的：观察BCM235缓释干混悬剂和布洛芬混悬液在健康人体中的安全性。

[Translation]

Preliminary test: Preliminary exploratory evaluation of the PK parameters of BCM235 sustained-release dry suspension and ibuprofen suspension to provide a basis for the next clinical study. Single/multiple-dose PK study: Main purpose: Using ibuprofen suspension produced by Shanghai Johnson Pharmaceutical Co., Ltd. as a control, study the pharmacokinetic characteristics and bioavailability of BCM235 sustained-release dry suspension, and investigate the bioequivalence between BCM235 sustained-release dry suspension and ibuprofen suspension. Secondary purpose: Observe the safety of BCM235 sustained-release dry suspension and ibuprofen suspension in healthy humans.

Start Date09 Nov 2022

Sponsor / Collaborator

Shanghai Bocimed Pharmaceutical Co., Ltd.

100 Clinical Results associated with BCM-235

Login to view more data

100 Translational Medicine associated with BCM-235

Login to view more data

100 Patents (Medical) associated with BCM-235

Login to view more data

100 Deals associated with BCM-235

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Arthralgia	Phase 1	China	Shanghai Bocimed Pharmaceutical Co., Ltd.	09 Nov 2022
Common Cold	Phase 1	China	Shanghai Bocimed Pharmaceutical Co., Ltd.	09 Nov 2022
Fever	Phase 1	China	Shanghai Bocimed Pharmaceutical Co., Ltd.	09 Nov 2022
Headache	Phase 1	China	Shanghai Bocimed Pharmaceutical Co., Ltd.	09 Nov 2022
Influenza, Human	Phase 1	China	Shanghai Bocimed Pharmaceutical Co., Ltd.	09 Nov 2022
Migraine Disorders	Phase 1	China	Shanghai Bocimed Pharmaceutical Co., Ltd.	09 Nov 2022
Mild pain	Phase 1	China	Shanghai Bocimed Pharmaceutical Co., Ltd.	09 Nov 2022
Moderate pain	Phase 1	China	Shanghai Bocimed Pharmaceutical Co., Ltd.	09 Nov 2022
Myalgia	Phase 1	China	Shanghai Bocimed Pharmaceutical Co., Ltd.	09 Nov 2022
Neuralgia	Phase 1	China	Shanghai Bocimed Pharmaceutical Co., Ltd.	09 Nov 2022